China Medicine Corp. buys LifeTech
This article was originally published in The Tan Sheet
Executive SummaryChina Medicine Corp. adds 39 traditional Chinese and Western medicines to its portfolio with the $8.3 million acquisition of Sinoform Ltd. and its subsidiary LifeTech Pharmaceuticals. The deal, expected to close by the end of the year, will add between $10 million and $12 million in revenues to China Medicine in 2010, the prescription and OTC drug distributor says Oct. 30. It also expects the acquisition of the British Virgin Islands firm to generate a net profit margin of at least 40 percent in 2010
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.